AstraZeneca COVID Vaccine Trial Exceeds Expectations After Controversy

|
|
Posted: Mar 22, 2021 11:00 AM
AstraZeneca COVID Vaccine Trial Exceeds Expectations After Controversy

Source: AP Photo/Kirsty Wigglesworth

Could a fourth COVID vaccine be on the horizon? There's been some controversy and negative coverage of AstraZeneca's shot, developed with the University of Oxford. The European Medicines Agency approved the shot in January, but at least 16 European countries stopped distribution of the vaccine due to concerns about blood clots. About 30 recipients of the vaccine, most of whom were women under the age of 55, were reportedly diagnosed with cerebral venous sinus thrombosis.

But a new U.S. clinical trial of 30,000 people has produced some positive results that may put those fears to rest. The trial "confirmed the safety profile of the vaccine," reports CNBC. The vaccine proved to be 79 percent effective in preventing symptomatic COVID, and 100 percent effective in preventing hospitalization.

The trial included over 30,000 participants and showed that the vaccine had an overall efficacy of 79% in preventing symptomatic Covid-19 and was 100% effective in preventing severe disease and hospitalization.

Efficacy was consistent across age and ethnic group, with 80% efficacy in participants aged 65 years and over. The vaccine, known as AZD1222 and developed with the University of Oxford, was well-tolerated and the independent data safety monitoring board identified no safety concerns related to the vaccine. 

A group of German researchers recently issued a statement connecting the vaccine to a risk of blood clots, but the U.S. trial appeared to upend that assessment.

Health experts say there should now be nothing holding AstraZeneca back from getting the FDA's blessing.

Recommended
Will the 'Great Replacement' Smear Work?
Scott Morefield

“I can’t see why the regulator wouldn’t approve it,” Adam Barker, healthcare analyst at Shore Capital, wrote.

Three COVID-19 vaccines are currently FDA approved, including those produced by Pfizer-BioNTech, Moderna, and Johnson & Johnson, the last of which only requires one dose.